{"paper_id":"2914129d-715e-43cf-9a0e-fce55591fe5c","body_text":"JS and BK designed the study. JS conducted the search. ATG, PB, GH, AK, LMN, JS, BK, and CH analyzed the data and interpreted the findings. LMN wrote and edited the manuscript with input from ATG, PB, GH, AK, JS, BK, and CH.\n\nAaron T. Gerds has served as a consultant for Celgene/Bristol Myers Squibb, Pfizer, Kartos Therapeutics, Promedior, and CTI BioPharma; Prithviraj Bose has received research support from Incyte, Bristol Myers Squibb, CTI BioPharma, Constellation/Morphosys, Kartos, Blueprint Medicines, Cogent, Pfizer, Astellas, NS Pharma and Promedior, and honoraria from Incyte, Bristol Myers Squibb, CTI BioPharma, Sierra Oncology, Abbvie, Constellation/Morphosys, Karyopharm, Pharma Essentia, Blueprint Medicines and Novartis; Gabriela S. Hobbs served as a consultant for Celgene/Bristol Myers Squibb, Pfizer, Blueprint Medicines, Incyte, Novartis, Abbvie, Keros and Pharmaxis; Andrew T. Kuykendall has received clinical research funding from Sierra Oncology, Constellation/Morphosys, and Celgene/Bristol Myers Squibb and has served on advisory boards for CTI Biopharma, Novartis, Abbvie, Celgene/Bristol Myers Squibb, Constellation/Morphosys, and Imago Biosciences; Lynn M. Neilson and Barbara Klencke are employees of Sierra Oncology; Jinlin Song is an employee of Analysis Group; and Claire Harrison has received clinical research funding from Novartis, Constellation, and Bristol Myers Squibb, and has served on advisory boards and as a speaker for Novartis, Celgene/Bristol Myers Squibb, CTI BioPharma, Gilead Sciences, Shire, Roche, Janssen, Promedior, Geron, AOP, Galecto, Sierra Oncology, Constellation, and Keros, and is Deputy Editor in Chief of HemaSphere.\n\nMomelotinib is sponsored by Sierra Oncology. The targeted literature search was performed by Analysis Group, which was sponsored by Sierra Oncology.\n\nAll data generated or analyzed during this study are included in this published article.","source_license":"CC0","license_restricted":false}